LG CHEM will launch the diabetes treatment combination drug “Zemidapa” in the Thai market. The company plans to continue exports to the Philippines, Mexico, and Brazil.
LG CHEM recently held the “Zemi-CONNECT Global” symposium in Bangkok, Thailand, for over 120 endocrinologists from Korea, Thailand, and the Philippines, and announced the Thai launch of Zemidapa and its global business plans on the 8th. This event was held during the International Diabetes Federation (IDF) 2025 General Assembly, where LG CHEM participated as a main sponsor.
Zemidapa is a combination drug of the first domestically produced diabetes treatment new drug DPP (dipeptidyl peptidase)-4 inhibitor “Zemiglo” and the SGLT (sodium-glucose co-transporter)-2 inhibitor component “Dapagliflozin.”
To enter the Thai market, LG CHEM prioritized establishing a direct sales base for the global market expansion of Zemidapa. According to market research firm IQVIA MIDAS, the overall market size for DPP-4 inhibitors and SGLT-2 inhibitor products in Thailand is expected to be approximately 250 billion won in 2024, with the market for combination drugs of these two classes showing a remarkable average annual growth of 36% over the past three years.
Zemidapa is the second drug to enter this Thai combination drug market, and the company plans to leverage the sales networks of Zemiglo and Zemimet already established in Thailand to create business synergies. Last year’s market share of Zemiglo and Zemimet in the Thai DPP-4 inhibitor market was approximately 13%.
Hwang In-cheol, head of LG CHEM’s Primary Care Division, said, “The importance of managing diabetes patients under 40 years old is gradually increasing in Thailand, so we expect the demand for combination drugs with strong blood glucose-lowering effects, such as Zemidapa and Zemimet, to continue to grow,” adding, “Starting with the entry of Zemidapa into Thailand, we will expand our business achievements in the ASEAN and Latin American markets.”